Compass Pathways ($CMPS): Can COMP360 Reach the Filing Finish Line?

01 Scenarios: the filing is the next test, approval is a separate decision

Compass Pathways enters October with positive pivotal depression data, a rolling application and a substantially enlarged balance sheet. The next investment question is whether those assets can become an approvable, deliverable treatment before the cost of launch preparation and the enlarged share count absorb too much of their value. In its September 9, 2026 update, Compass targeted completion of the COMP360 application in the fourth quarter of 2026 and a potential launch in the first half of 2027, subject to FDA approval and controlled-substance rescheduling. Those are company expectations, not an announced FDA decision date. Source

Bull case: a complete application and a workable launch

The favorable scenario requires Compass to complete its application within its stated fourth-quarter 2026 window, obtain an acceptable regulatory outcome and translate its preparation into treatment capacity. The September 9 open-label follow-up would support the durability discussion alongside the controlled evidence, without being asked to prove more than its design permits. The company would retain financial flexibility while providers and payors resolve practical access questions. In this scenario, regulatory progress reduces uncertainty before launch spending consumes a disproportionate part of the June 30, 2026 cash balance of $433.295 million. The filing target and cash are disclosed facts; the favorable outcome is conditional. Source Source

An approval alone would not establish the full constructive case. The label, any required risk-management arrangements, treatment-site readiness, reimbursement and the speed of patient starts would determine whether an approved medicine becomes a business. Compass’s August 5, 2026 update explicitly included site training, certification, reimbursement assistance and patient support in its launch work. Progress on those tasks would make the revenue thesis more credible than another broad description of market size. Source

Base case: progress with an uneven transition

The middle scenario assumes the application advances but the transition takes longer or costs more than investors expect. Providers could prepare ahead of authorization while commercial throughput remains uncertain. A treatment requiring supervised administration does not necessarily convert awareness into prescriptions and cash at the speed of an ordinary retail medicine. The company’s August 5, 2026 funding guidance extends into 2028, but it remains a budget based on assumptions about development, launch and operating costs. Slower uptake could use that capacity without invalidating the controlled clinical results. Source Source

Bear case: delay, restrictions or weak economics

The adverse scenario would arise if regulators seek substantial additional evidence, impose conditions that materially constrain access, or if reimbursement and delivery economics frustrate adoption. A further financing could then spread any eventual value across more shares. The June 30, 2026 accounts already include 23.849 million pre-funded warrants and 11.904 million equity-classified warrants, in addition to issued shares. The precise cost of a setback therefore depends on both the cash spent while waiting and the securities used to finance the wait. This is a risk scenario, not a claim that the FDA has requested another trial. Source

What Would Falsify This Reading

The constructive reading requires regulatory progress and a practical treatment model, while preserving enough financial flexibility to execute. These developments would weaken it.

• The filing window moves without a credible explanation. A material delay or additional evidence requirement would challenge the fourth-quarter 2026 completion target disclosed September 9. It would need to be evaluated for its effect on both timing and cash. Source
• Clinical benefit becomes harder to deliver. A restrictive treatment setting, weak reimbursement or less durable real-world benefit could undermine the operating thesis even after an approval. The August 5 launch plan depends on training, certification and access work. Source
• Cash use and dilution outrun useful progress. A materially higher spending rate without corresponding regulatory or operational progress would weaken the flexibility implied by June 2026 cash. Pre-funded warrants already financed are not another large source of future cash. Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 What the next catalyst actually is

The clearest near-term milestone is completion of the rolling New Drug Application for COMP360 in treatment-resistant depression. Compass said on September 9, 2026 that submission and initial review were underway and it expected to complete the application in the fourth quarter of 2026. The distinction matters: sending modules progressively is a regulatory process; completing an application, obtaining its acceptance and receiving an approval are different events. A headline about one does not confirm all the others. Source

The August 5, 2026 results release said Compass had received a National Priority Voucher, with the potential to shorten review. It also warned that the rolling process and the voucher might not result in a faster review or approval. A trader should therefore look for the actual next regulatory communication and its scope, rather than calculate an approval day from a promotional review-duration estimate. The application can progress without yet providing a fixed date on which the FDA must decide. Source

The company’s first-half 2027 commercial-launch expectation, reiterated September 9, 2026, also depends on FDA approval and DEA rescheduling. Its August 5 update discussed state-level scheduling work as a further part of launch preparation. The practical sequence is a usable regulatory authorization, the necessary controlled-substance permissions and sites able to treat eligible patients. These steps may overlap in preparation, but none of them means that sales have begun. Source Source

To pass the next catalyst, Compass needs to deliver the application completion it has promised and explain any change in scope or timing. After that, the test shifts to the review, proposed treatment conditions and eventual commercial implementation. An additional follow-up analysis could strengthen the medical narrative, but it would not substitute for a complete regulatory package. Conversely, a delay in administrative completion would need to be understood before assuming that the clinical effect itself had disappeared.

A conference appearance is a communication opportunity, not automatically a new result. The September educational campaign and training awards are evidence of preparation. The dated filing target remains the relevant event to monitor; no future conference date is necessary to make that calendar look busier. A useful update would reduce uncertainty about the filing or the conditions of treatment, rather than simply repeat the potential size of the depression market. Source Source Source

03 The controlled results: the size of the effect matters

COMP360 is Compass’s investigational synthetic psilocybin treatment. Its clinical proposition is an improvement in depressive symptoms that can begin quickly and persist between supervised administrations. The business thesis rests on the observed benefit, safety and deliverability of that treatment, rather than on the novelty of the psychedelic category itself. Source

The first pivotal study, COMP005, included 258 dosed participants, with 171 receiving the 25 mg dose and 87 placebo. In the company’s February 17, 2026 summary of its previously reported primary result, the difference in change in the MADRS depression score at six weeks was −3.6 points in favor of COMP360; the 95% confidence interval was −5.7 to −1.5 and p<0.001. A lower MADRS score means fewer measured symptoms. The comparison supports efficacy in that study; it does not mean every treated patient benefited by that amount. Source

The second pivotal study, COMP006, had 581 dosed participants overall, including 296 in the 25 mg group and 143 in the 1 mg comparison group. Its February 17, 2026 primary result showed a −3.8-point treatment difference at six weeks, with a 95% confidence interval of −5.8 to −1.8 and p<0.001. This provides another controlled result in the same development program. It is more informative than simply counting how many trials were described as positive, because it gives the magnitude, uncertainty and relevant comparison. Source

The p-values address evidence against the statistical null in those comparisons. They are not the probability that the medicine will be approved, a prediction of commercial success or the proportion of patients who improved. Clinical usefulness also depends on how many patients obtain a meaningful benefit, how long it lasts and what burden accompanies treatment. A modest average difference can coexist with substantial benefit in some patients and little benefit in others.

Compass’s July 7, 2026 update said 39% of the COMP006 25 mg group achieved at least a 25% MADRS reduction at week six and maintained benefit, on average, through at least week 26. That threshold is not the same as the conventional response measure of at least a 50% reduction used in the September open-label update. The company compared the 39% figure with 25% in COMP005, but that is a comparison across studies, not a randomized test proving one dosing approach superior to the other. Source Source

For the stock, these distinctions prevent two opposite mistakes: dismissing a reproducible controlled signal because not everyone responds, or treating a selected group of improving patients as though it represented the whole treated population. The next regulatory judgment concerns the complete benefit-risk package. The commercial judgment will then concern the population, treatment conditions and outcomes that actually reach practice.

04 September’s one-year data: useful, with a different denominator

The September 9, 2026 announcement described the open-label extension of COMP005 through week 52. In that extension, 90 participants previously assigned to 25 mg received another 25 mg administration, while 52 participants previously assigned to placebo received their first active administration. These are the relevant treated groups for the new observations. They are not all 258 participants originally dosed in the pivotal study, and the extension does not supply a new randomized comparison with placebo. Source

Compass reported an average MADRS reduction from the original baseline of 13 points at week 52 in the previously treated group that received an additional dose, and 10 points in the former-placebo group receiving active treatment during the extension. Those are within-group changes. They do not replace the −3.6-point placebo-adjusted primary result and do not show a controlled treatment advantage at one year. Source Source

The same September 9 announcement reported response rates of 40–45% and remission of approximately 30% across the measurements from the day after administration through six weeks after the extension dose. Here response meant at least a 50% MADRS reduction. Those observations are relevant to repeat treatment, but they do not establish that every responder maintained an uninterrupted response for a full year. The treatment timing, retained population and definition of benefit all differ from a headline claiming one dose worked for everyone for a year. Source

The investor value of this follow-up is the additional information it gives about retreatment and longer-term observation. It helps develop a more realistic treatment model: a patient may need reassessment and further treatment, and the benefit may vary over time. The limitation is equally practical. Open-label observations can support a durability discussion, but expectations and the selection of patients remaining in follow-up affect interpretation. The controlled studies remain the stronger anchor for the comparative efficacy claim.

A favorable future update would explain the duration and distribution of benefit with denominators that can be followed. An unfavorable one might show that the patients likely to use the treatment obtain less durable benefit than expected, increasing the treatment burden. Neither possibility can be settled by transferring a p-value from the controlled phase to the open-label extension.

What the retreatment observations can and cannot finance

The September dataset changes the questions for a possible treatment service. If another dose can restore benefit in patients whose improvement has weakened, a clinic may need to reserve capacity for returning patients as well as first treatments. The relevant planning variable is therefore not simply the number of unique patients treated each year. It also includes how many supervised sessions each patient needs, how far apart those sessions occur and how many sessions the same team can safely deliver. The open-label observations support investigating that model. They do not establish a reimbursed maintenance schedule or a predictable annual revenue per patient.

In particular, the approximately 40–45% response and 30% remission figures reported six weeks after retreatment are not the proportions of every original randomized participant who remained well for one year. Patients entering Part C form a selected follow-up population. Some had previously received active treatment and some placebo, and the published changes after another dose are within-group observations. Attrition, eligibility for retreatment and the absence of a concurrent randomized comparison limit causal interpretation. A future label would need to specify the supported population and dosing conditions; commercial planning cannot assume that every possible repeat-treatment pattern is authorized.

The distinction also matters when comparing COMP005 with COMP006. A mean MADRS difference describes the average separation between randomized treatment groups, while a response threshold classifies individual patients. The July percentage achieving at least a 25% reduction is not interchangeable with a conventional response definition requiring a 50% reduction. Replacing one threshold with the other would make the apparent benefit larger without adding any clinical evidence. Likewise, the September absolute reductions after retreatment cannot be inserted into the randomized six-week comparison as if they were another estimate from the same design.

05 Safety and the additional PTSD opportunity

The July 7, 2026 COMP006 update reported serious adverse events in 5.7% of participants in the 25 mg group and 6.3% in the 1 mg group over 26 weeks. The most common treatment-emergent events included nausea, headache, anxiety and visual hallucination; the company said most were transient and concentrated around administration. These figures are more useful than an unqualified statement that the drug is safe. They describe the study population and observation period, not the absence of risk in every future patient. Source

The February 17, 2026 update reported serious suicidal-ideation events at less than 1% across the available data from the two studies and a single serious suicidal-behavior event in the COMP006 1 mg group. The company’s independent monitoring-board statement did not identify a clinically meaningful imbalance between arms. That is reassuring within the dataset, but depression severity and supervision remain central to interpreting the treatment. A statement that no new safety finding was reported does not remove the need for patient selection, observation and follow-up. Source

Compass also has a PTSD program. Its August 5, 2026 update described a late-stage study as underway. That provides another potential development opportunity, but it is separate from the depression application and does not add an approved indication to COMP360. The near-term cash and regulatory thesis should be able to stand on the depression program without assigning full commercial value to a second indication that has not completed its pivotal evidence package. Source

The question for the next regulatory update is how efficacy and safety translate into the permitted treatment setting. More demanding observation or staffing requirements could protect patients while increasing the cost and time needed to deliver treatment. A workable model has to accommodate both objectives. For investors, safety is therefore also an operating variable, not simply a box checked after an efficacy announcement.

06 A potential product needs treatment capacity

Compass is preparing to sell a medicine within a supervised treatment pathway, rather than a product whose entire commercial task ends when a prescription is written. Its August 5, 2026 update identified provider education, training, potential REMS certification, reimbursement assistance and patient support as launch activities. Existing treatment infrastructure may help, but the relevant measure is how much of it becomes appropriately prepared and economically willing to deliver COMP360 if authorized. Source

On September 10, 2026, Compass announced grants to five organizations developing provider training. The announcement stated that the recipients would retain independent control of their programs and framed the work around a potential post-approval launch. Funding education is a concrete preparation step. It is not evidence that those organizations represent a booked patient pipeline, a guaranteed volume of treatments or an already approved commercial network. Source

On September 15, 2026, the company launched its U.S. “Change the Tune in TRD” education initiative for healthcare professionals. The campaign concerns recognition and care pathways in treatment-resistant depression. It can support awareness and relationships before a potential launch, but it does not establish COMP360 revenue or change its investigational status. That distinction matters when interpreting news flow during a period with substantial promotional preparation and few discrete regulatory decisions. Source

The economic question is who is paid for each part of treatment and whether that payment covers the time, staff and facilities required. Compass must establish the product’s place in that pathway; providers must be able to operate it; patients must be able to access it. A large addressable population does not by itself solve referral, coverage or capacity constraints. Demand can exist while the rate of actual treatment remains limited.

Early commercial evidence, if approval is obtained, should therefore be judged through patient starts, active sites, treatment completion, coverage and cash collection. The number of trained providers would be useful context, but it would not be interchangeable with productive capacity. These distinctions also explain why a slow opening period could reflect implementation rather than a sudden reversal of the clinical results.

An illustrative capacity calculation, not a launch forecast

Consider a hypothetical service with ten supervised treatment places, each able to accommodate one session per working day for 220 days. Its arithmetic ceiling would be 2,200 sessions a year before downtime, staffing gaps, screening failures or cancellations. If every patient received one session, that ceiling would correspond to 2,200 patients. If the average were two sessions, it would correspond to 1,100 patients. These are deliberately illustrative assumptions, not Compass guidance and not a claim about the approved protocol. They show why the number of treatment centers alone cannot establish the size of a launch.

A stronger commercial update would connect several operational measures: trained staff, available supervised sessions, eligible referrals, actual treatment starts and the proportion of completed treatments paid for by insurers. A center that has signed an agreement but has no trained team or funded patient pathway creates little immediate throughput. Conversely, greater utilization of an existing center may matter more than another logo on a network map. The filing and potential launch windows provide a timetable for monitoring those measures, but that timetable does not translate into an assumed number of prescriptions.

07 Cash, monthly consumption and the runway

Compass reported $433.295 million of cash and cash equivalents at June 30, 2026. Restricted cash of $0.425 million was separate and is excluded from the available-cash calculation here. The balance had grown from $149.608 million of unrestricted cash at December 31, 2025, primarily because of financing, not product sales. The company remained without product revenue in the June accounts. Source

Operating activities consumed $88.242 million during the first half of 2026, compared with $84.346 million in the first half of 2025. Dividing the current-period outflow by six gives a calculated historical monthly consumption of $14.707 million. Dividing June’s unrestricted cash by that monthly rate gives approximately 29.5 months. This is a static sensitivity calculation from a past period, not the company’s forecast, not an October cash balance and not a precise date on which funds will run out. Source

The company’s August 5, 2026 guidance said its cash could fund operating expenses and capital expenditure into 2028. That is the appropriate management runway statement. The historical calculation helps assess the scale of the balance, while the guidance incorporates a forward plan. They need not produce an identical duration because launch preparation, trials, working capital and financing can change subsequent cash flows. The two descriptions are separate, and the longer one is not a certainty. Source Source

The cash flow also explains why the reported loss is a poor burn proxy. The second-quarter 2026 net loss was $253.794 million, including a $205.577 million noncash loss from the remeasurement of warrant liabilities. For the first half, net loss was $162.592 million and the warrant remeasurement loss was $74.661 million. Those accounting movements are not additional operating cash paid out. Using the quarterly net loss as the spending rate would materially distort liquidity. Source

There is nevertheless a real cost trend to watch. General and administrative expense rose to $23.197 million in the second quarter of 2026 from $12.608 million a year earlier, with commercial preparation a major driver. Research and development expense declined to $29.175 million from $30.325 million over the same comparison. Spending is changing composition as the company prepares for a possible launch; lower trial expense does not imply that total cash needs must fall. Source

After June, the company received $31.7 million in aggregate proceeds from ATM sales and PIPE-warrant exercises through July 30, 2026. That is a subsequent financing disclosure, not part of the June cash balance. Adding it to June cash without subtracting intervening operating outflows would create a misleading current-cash estimate. The next quarterly balance will show the net effect of those inflows and the spending that followed. Source

Stress-testing the reported cash baseline

Using the June unrestricted cash balance of $433.295 million and first-half operating cash use of $88.242 million gives average monthly consumption of $14.707 million and a static coverage ratio of approximately 29.5 months. Restricted cash is excluded. This is a historical quotient, not management guidance and not a forecast from October 4: spending and financing after June are not supplied by that equation. The company’s stated funding horizon into 2028 is a separate forward-looking assessment incorporating its own planned expenditure.

Two sensitivities make the distinction concrete. If average monthly operating cash use were 25% higher than the first-half rate, the same starting balance would cover approximately 23.6 months; at 50% higher, about 19.6 months. These calculations assume no financing, no investment return and no other cash movements. They are not predictions of launch expense or clinical spending. Their purpose is to show that a large cash balance can support a substantial program while still being sensitive to a simultaneous filing, manufacturing and commercial buildout. Additional borrowing or warrant exercises should enter the analysis only when their conditions and actual proceeds are disclosed.

08 Debt: available capacity has conditions

At June 30, 2026, Compass’s Hercules loan had $50 million of principal and a $50.727 million carrying value. The January 2026 amendment expanded the maximum facility to $150 million, but the remaining capacity was not all unrestricted cash available on demand. Additional tranches depend on regulatory or commercial milestones and, for part of the facility, investment-committee approval. The unused headline capacity should therefore not be added automatically to the runway. Source

Under the terms disclosed in the June 30, 2026 accounts, cash interest is based on the greater of 9.75% or the Wall Street Journal prime rate plus 2.75%. Principal payments begin in the first quarter of 2029, with possible deferral if conditions are met, and scheduled maturity is January 5, 2031. The absence of near-term principal amortization helps liquidity, while interest remains a recurring cost. The reported effective rate was 12.9% at June 30, reflecting the economics beyond the stated cash-rate formula. Source

A minimum-cash covenant starts on October 1, 2027 and generally requires cash equal to at least 55% of outstanding debt. The June filing describes adjustments linked to performance milestones and a market-capitalization condition for a possible exemption. Compass reported compliance at June 30, 2026. The future covenant matters because the amount that can be spent freely may eventually be less than the bank balance, especially if more debt is drawn. Source

Debt can reduce the immediate need to issue shares, but it trades some dilution for interest, covenants and repayment obligations. Equity provides more operating flexibility while increasing the denominator. Neither form of financing is free. The useful question is whether new funding carries the company through a value-creating milestone on terms that leave shareholders a meaningful share of the resulting business.

09 Shares, warrants and financing capacity

Compass had 135,722,306 ordinary shares outstanding at June 30, 2026 and 138,476,822 at July 30, 2026 on the quarterly report’s cover. Each Nasdaq ADS represents one ordinary share. The later cover count is the issued-share reference here; the June equity-instrument table is a separate snapshot. The difference in dates matters because financing continued after the balance-sheet date. Source

At June 30, 2026, 23,848,829 pre-funded warrants remained outstanding. They have a nominal exercise price and their substantial purchase consideration has already been paid. Their eventual exercise can increase reported shares without delivering meaningful new financing. A valuation that counts only issued shares but assumes future cash from these instruments would make two mistakes in the same direction. Source

The June 30, 2026 equity-classified warrant count was 11,903,922, including 11,809,700 remaining PIPE warrants with a $9.93 exercise price and an exercise period ending in February 2027. Full cash exercise of the PIPE warrants could have produced approximately $117.3 million at that June snapshot. The same filing’s later risk discussion reduced the potential proceeds to $105.8 million as of August 3, 2026. Both are conditional amounts; holders are not required to exercise, and qualifying cashless exercise would not produce equivalent proceeds. Source

The other material June 30, 2026 instruments included 9,852,870 options and 1,522,818 unvested restricted share units. These are potential claims on future shares, not all immediately issued stock. The 2020 incentive plan also allows an annual increase of up to 4% of prior year-end shares, subject to the committee’s discretion; 3,656,273 shares remained available for future awards under that plan at June 30. Incentive reserves and future annual increases are not cash already raised. Source

The February 2025 ATM program permits up to $150 million of sales. Through July 30, 2026, Compass reported 2,798,696 ADSs sold under that program for $33.1 million of net proceeds. Net proceeds are not the same as gross authorization used, so subtracting the net figure from the program ceiling would not give an exact remaining capacity. The important point is that the company has already used the facility while preparing for a potential launch. Source

For a trader, dilution is most useful when tied to purpose. Financing ahead of a binary decision can strengthen the ability to execute afterward. It also means that a successful regulatory outcome accrues to a larger share base. The next balance sheet should be read with both the cash bridge and the share bridge open, including pre-funded instruments that have already supplied cash but may not yet appear in issued shares.

10 Ownership, insider transactions and short positioning

Finviz data as of October 2, 2026 showed a float of 136.24 million shares, short interest equal to 11.18% of float and a short ratio of 4.57. These are dated third-party figures; the data date is not a new exchange settlement date. The same data showed institutional ownership of 64.69% and insider ownership of 1.61%. Different reporting schedules and definitions mean these figures may not reconcile exactly with every beneficial-ownership filing. Source

RTW’s May 15, 2026 filing reported beneficial ownership of 12,971,571 shares, or 9.9%, for the March 31, 2026 reporting date, including 2,339,181 shares assumed issuable through warrants. This is a named holder’s disclosed position at that date, not an October holdings claim. It illustrates why a beneficial position may include more than delivered shares and why a data aggregator’s institutional percentage is not a substitute for the underlying ownership disclosure. Source

AtaiBeckley’s February 17, 2026 filing reported 4,764,710 shares as of January 21 and said it had fallen below the 5% reporting threshold after open-market sales. That is an actual disposal history by a significant holder. It is distinct from management payroll withholding and is not evidence of what the holder did months later. Source

The Form 4 filed on August 5, 2026 records CEO Kabir Nath having 5,962 shares withheld on August 3, 2026 to satisfy tax obligations associated with vesting. The filing explicitly describes withholding by the issuer. Calling it a discretionary market sale would misstate the transaction. It also does not establish a fresh open-market purchase by the CEO. Source

The reference price is $11.95 at the October 1, 2026 close in Finviz’s daily series. That price is a dated observation, not a target. Short positioning can amplify reactions around regulatory news, but it cannot establish which scenario will occur; the application, cash use and terms of access remain the underlying drivers. Source Source

11 Red flags that would change the interpretation

The first warning would be an unexplained change in the fourth-quarter 2026 application-completion window. A delay is not automatically a failed drug, but its reason matters: missing manufacturing information, additional clinical work and ordinary submission logistics have different implications for time and funding. The September 9 target should be assessed against the next company’s actual regulatory update rather than carried forward indefinitely. Source

The second warning would be a treatment model that is clinically useful but difficult to deliver at an acceptable cost. Training announcements can show preparation while leaving reimbursement, staffing and productive site capacity unresolved. If a future label or commercial experience requires greater resources than anticipated, launch economics could weaken even with an approval. The August 5 description of launch work makes those operating dependencies explicit. Source

The third warning would be a cash-consumption increase without corresponding progress toward filing or commercial readiness. The historical $14.707 million monthly operating rate is a first-half 2026 calculation, not a spending limit. A higher future rate needs an explanation tied to specific work and expected milestones. Likewise, issuance that increases shares much faster than it extends useful financial flexibility would change the balance of the thesis. Source

Finally, follow-up results are meaningful only with their actual denominator and comparison. The September 9 open-label data can be encouraging without proving a one-year controlled advantage or universal durable response. Overstating that evidence would make the investment narrative less robust precisely when regulatory scrutiny is most consequential. Source

12 What to watch and the bottom line

The next useful update should answer a short sequence of practical questions: has the application been completed within the company’s window; has the regulator clarified the next step; what treatment conditions are emerging; and does the balance sheet still support execution? If approval follows, attention should move to scheduling, functioning treatment sites, patient access and collected revenue. Each step changes the evidence needed for the next one.

Financially, the next results should reconcile the June 30, 2026 cash base, the disclosed financing after June, operating outflows and the enlarged share count. The company has more capacity than before its 2026 financing, but capacity does not make all future spending productive. The debt’s conditions and outstanding equity instruments remain relevant even when the immediate cash position looks comfortable. Source

Compass offers a defined regulatory transition supported by positive controlled trials and further open-label follow-up. The central uncertainty has shifted toward the complete benefit-risk judgment and the practical economics of delivering treatment, while clinical and financing risks remain. The September 9, 2026 filing and launch expectations provide a calendar to test. They do not provide an approval guarantee or a valuation conclusion. This hub describes the evidence and the conditions that would change the reading; it does not recommend buying or selling the shares. Source